[go: up one dir, main page]

EA202092320A1 - Гетеробициклические ингибиторы mat2a и способы использования для лечения злокачественной опухоли - Google Patents

Гетеробициклические ингибиторы mat2a и способы использования для лечения злокачественной опухоли

Info

Publication number
EA202092320A1
EA202092320A1 EA202092320A EA202092320A EA202092320A1 EA 202092320 A1 EA202092320 A1 EA 202092320A1 EA 202092320 A EA202092320 A EA 202092320A EA 202092320 A EA202092320 A EA 202092320A EA 202092320 A1 EA202092320 A1 EA 202092320A1
Authority
EA
Eurasian Patent Office
Prior art keywords
treatment
methods
heterobicyclic
malignant tumor
mat2a inhibitors
Prior art date
Application number
EA202092320A
Other languages
English (en)
Inventor
Зинон Д. Контитис
Минцзун Ли
Пэн ЛЮ
Мэттью Медейрос
Сэмьюэл К. Резник
Чжихуа Суй
Джереми М. Трэвинс
Джанета Поповичи-Мюллер
Шубао Чжоу
Гуаннин Ма
Original Assignee
Аджиос Фармасьютикалз, Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Аджиос Фармасьютикалз, Инк. filed Critical Аджиос Фармасьютикалз, Инк.
Publication of EA202092320A1 publication Critical patent/EA202092320A1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/20—Spiro-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/527—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim spiro-condensed
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)

Abstract

Настоящее изобретение относится к соединениям в соответствии с формулой (I) или формулой (II) и их фармацевтически приемлемым солям, стереоизомерам и/или таутомерам, описанным в настоящем изобретении. Также предложены фармацевтические композиции и способы применения соединений для лечения злокачественных опухолей, включая некоторые злокачественные опухоли, у которых делетирован ген, кодирующий метилтиоаденозин-фосфорилазу (МТАР).
EA202092320A 2018-03-30 2019-03-28 Гетеробициклические ингибиторы mat2a и способы использования для лечения злокачественной опухоли EA202092320A1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN2018081328 2018-03-30
PCT/US2019/024645 WO2019191470A1 (en) 2018-03-30 2019-03-28 Heterobicyclic inhibitors of mat2a and methods of use for treating cancer

Publications (1)

Publication Number Publication Date
EA202092320A1 true EA202092320A1 (ru) 2021-03-09

Family

ID=67439309

Family Applications (1)

Application Number Title Priority Date Filing Date
EA202092320A EA202092320A1 (ru) 2018-03-30 2019-03-28 Гетеробициклические ингибиторы mat2a и способы использования для лечения злокачественной опухоли

Country Status (22)

Country Link
US (1) US11524960B2 (ru)
EP (1) EP3774805B1 (ru)
JP (2) JP7350005B2 (ru)
KR (1) KR102736073B1 (ru)
CN (1) CN111936499B (ru)
AR (1) AR115326A1 (ru)
AU (1) AU2019243289B2 (ru)
BR (1) BR112020020104A2 (ru)
CA (1) CA3094476A1 (ru)
EA (1) EA202092320A1 (ru)
ES (1) ES2973114T3 (ru)
HU (1) HUE066282T2 (ru)
IL (1) IL277665B2 (ru)
MA (1) MA52232A (ru)
MX (1) MX2020010005A (ru)
NZ (1) NZ767697A (ru)
PH (1) PH12020551507A1 (ru)
PL (1) PL3774805T3 (ru)
SG (1) SG11202009195WA (ru)
TW (1) TWI719437B (ru)
UA (1) UA127059C2 (ru)
WO (1) WO2019191470A1 (ru)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2019395338A1 (en) 2018-12-10 2021-07-29 Ideaya Biosciences, Inc. 2-oxoquinazoline derivatives as methionine adenosyltransferase 2A inhibitors
KR102823567B1 (ko) * 2018-12-27 2025-06-20 르 라보레또레 쎄르비에르 Mat2A의 AZA-헤테로이환 억제제 및 암 치료를 위한 사용 방법
US20220098203A1 (en) * 2018-12-27 2022-03-31 Les Laboratoires Servier Sas Aza-heterobicyclic inhibitors of mat2a and methods of use for treating cancer
AU2020284018A1 (en) * 2019-05-31 2022-01-27 Les Laboratoires Servier Heterobicyclic inhibitors of MAT2A and methods of use for treating cancer
WO2021252681A1 (en) * 2020-06-10 2021-12-16 Ideaya Biosciences, Inc. Quinolinone derivatives as methionine adenosyltransferase 2a inhibitors
US20240208965A1 (en) * 2020-06-10 2024-06-27 Ideaya Biosciences, Inc. Heteroaryl alkylene substituted 2-oxoquinazoline derivatives as methionine adenosyltransferase 2a inhibitors
US20230257359A1 (en) * 2020-06-10 2023-08-17 Ideaya Biosciences, Inc. 4-arylquinazoline derivatives as methionine adenosyltransferase 2a inhibitors
EP4165040A1 (en) * 2020-06-10 2023-04-19 Ideaya Biosciences, Inc. 2-aminoquinazolinone derivatives as methionine adenosyltransferase 2a inhibitors
CN115960098A (zh) * 2020-09-11 2023-04-14 上海凌达生物医药有限公司 一类含氮稠环类化合物的制备方法和用途
CN115916778A (zh) * 2020-09-12 2023-04-04 赛诺哈勃药业（成都）有限公司 甲硫氨酸腺苷转移酶抑制剂、其制备方法及应用
CN115960099A (zh) * 2020-09-24 2023-04-14 上海凌达生物医药有限公司 一类芳环或芳基杂环并吡啶酮类化合物、药物组合物及其应用
CN114507231B (zh) * 2020-11-17 2025-06-03 南京再明医药有限公司 内酰胺类化合物及其制备方法
CN114634521A (zh) * 2020-12-15 2022-06-17 首药控股(北京)股份有限公司 Dna-pk选择性抑制剂及其制备方法和用途
CN116670144A (zh) 2020-12-31 2023-08-29 南京再明医药有限公司 三环类化合物及用途
WO2022206730A1 (zh) * 2021-03-29 2022-10-06 武汉人福创新药物研发中心有限公司 嘧啶并吡嗪酮化合物及其用途
CN115215862A (zh) * 2021-04-19 2022-10-21 武汉人福创新药物研发中心有限公司 嘧啶酮化合物及其用途
WO2022253242A1 (zh) * 2021-06-02 2022-12-08 南京正大天晴制药有限公司 蛋氨酸腺苷转移酶2a抑制剂
CN118434722A (zh) 2021-10-20 2024-08-02 英矽智能科技知识产权有限公司 甲硫氨酸腺苷转移酶2a(mat2a)抑制剂及其用途
CN118265700A (zh) * 2021-11-09 2024-06-28 上海海雁医药科技有限公司 取代的萘啶酮衍生物、其药物组合物及应用
CN114028572B (zh) * 2021-11-30 2022-11-25 清华大学 Mat2a抑制剂用于治疗哮喘的新应用
WO2023116696A1 (zh) * 2021-12-21 2023-06-29 南京正大天晴制药有限公司 蛋氨酸腺苷转移酶2a的杂环抑制剂
WO2023125737A1 (en) * 2021-12-29 2023-07-06 Silexon Ai Technology Co., Ltd. Heterocyclic compounds and use thereof
KR20240138099A (ko) * 2022-01-26 2024-09-20 쑤저우 젠하우스 바이오 컴퍼니 리미티드 Mtap 결실 암을 치료하기 위한 메티오닌 아데노실트랜스퍼라제 2a 억제제
CN118742550A (zh) * 2022-03-11 2024-10-01 赛诺哈勃药业（成都）有限公司 甲硫氨酸腺苷转移酶抑制剂、其制备方法及应用
KR20250016234A (ko) 2022-06-27 2025-02-03 씨에스피씨 종콰이 팔마씨우티컬 테크놀로지 (스자좡) 컴퍼니 리미티드 삼환 화합물 및 이의 용도
CN117430596A (zh) * 2022-07-13 2024-01-23 上海海和药物研究开发股份有限公司 二并环类mat2a抑制剂及其用途
CN120077041A (zh) 2022-10-13 2025-05-30 韩美药品株式会社 新颖三环衍生物化合物以及其应用
WO2024183778A1 (zh) * 2023-03-06 2024-09-12 甘李药业股份有限公司 一种甲硫氨酸腺苷转移酶2a抑制剂及其医药用途
WO2024229406A1 (en) 2023-05-04 2024-11-07 Revolution Medicines, Inc. Combination therapy for a ras related disease or disorder
WO2024255805A1 (zh) * 2023-06-14 2024-12-19 南京正大天晴制药有限公司 蛋氨酸腺苷转移酶2a杂环抑制剂的晶型、其制备方法及用途
WO2025000265A1 (en) * 2023-06-28 2025-01-02 Silexon Ai Technology Co., Ltd. Heterocyclic compounds usefull as sos1 inhibitor
WO2025034702A1 (en) 2023-08-07 2025-02-13 Revolution Medicines, Inc. Rmc-6291 for use in the treatment of ras protein-related disease or disorder
US20250154171A1 (en) 2023-10-12 2025-05-15 Revolution Medicines, Inc. Ras inhibitors
WO2025088571A1 (en) * 2023-10-26 2025-05-01 Astrazeneca Ab Crystalline forms of tead inhibitor
CN117567473B (zh) * 2023-11-09 2025-07-04 中国药科大学 一种靶向同源二聚体的抑制剂及其制备方法与应用

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2002517486A (ja) 1998-06-12 2002-06-18 バーテックス ファーマシューティカルズ インコーポレイテッド ｐ３８のインヒビター
US6576420B1 (en) 1998-06-23 2003-06-10 Regents Of The University Of California Method for early diagnosis of, and determination of prognosis in, cancer
AU2003250466A1 (en) 2002-08-13 2004-02-25 Warner-Lambert Company Llc 3-isoquinolinone derivatives as matrix metalloproteinase inhiitors
BR112012010085B1 (pt) * 2009-10-29 2020-02-04 Genosco composto, quantidade terapeuticamente eficaz de um composto, formulação farmacêutica
US20160115164A1 (en) 2014-10-22 2016-04-28 Incyte Corporation Bicyclic heterocycles as fgfr4 inhibitors
MA41551A (fr) * 2015-02-20 2017-12-26 Incyte Corp Hétérocycles bicycliques utilisés en tant qu'inhibiteurs de fgfr4
EP3481830B1 (en) * 2016-07-05 2022-02-16 The Broad Institute, Inc. Bicyclic urea kinase inhibitors and uses thereof
WO2018039972A1 (en) * 2016-08-31 2018-03-08 Agios Pharmaceuticals, Inc. Inhibitors of cellular metabolic processes
US10329298B2 (en) * 2016-08-31 2019-06-25 Agios Pharmaceuticals, Inc. Inhibitors of cellular metabolic processes

Also Published As

Publication number Publication date
PL3774805T3 (pl) 2024-05-06
CA3094476A1 (en) 2019-10-03
WO2019191470A8 (en) 2019-12-12
KR20200138769A (ko) 2020-12-10
EP3774805B1 (en) 2024-01-10
BR112020020104A2 (pt) 2021-01-26
MX2020010005A (es) 2020-10-14
AU2019243289B2 (en) 2023-01-12
ES2973114T3 (es) 2024-06-18
KR102736073B1 (ko) 2024-12-02
AU2019243289A1 (en) 2020-09-24
UA127059C2 (uk) 2023-03-29
TWI719437B (zh) 2021-02-21
US11524960B2 (en) 2022-12-13
SG11202009195WA (en) 2020-10-29
JP7350005B2 (ja) 2023-09-25
NZ767697A (en) 2025-02-28
IL277665B2 (en) 2023-06-01
HUE066282T2 (hu) 2024-07-28
JP2021519783A (ja) 2021-08-12
WO2019191470A1 (en) 2019-10-03
CN111936499A (zh) 2020-11-13
MA52232A (fr) 2021-02-17
EP3774805A1 (en) 2021-02-17
PH12020551507A1 (en) 2021-09-13
TW201946629A (zh) 2019-12-16
IL277665A (en) 2020-11-30
JP2023101762A (ja) 2023-07-21
AR115326A1 (es) 2020-12-23
CN111936499B (zh) 2023-09-19
US20210115045A1 (en) 2021-04-22

Similar Documents

Publication Publication Date Title
EA202092320A1 (ru) Гетеробициклические ингибиторы mat2a и способы использования для лечения злокачественной опухоли
CR20210670A (es) Inhibidores aza-heterobicíclicos de mat2a y métodos de uso para tratar el cáncer
EA202191801A1 (ru) Гетероциклические ингибиторы mat2a и способы применения для лечения рака
PH12021551493A1 (en) Aza-heterobicyclic inhibitors of mat2a and methods of use for treating cancer
PH12020551717A1 (en) Dual atm and dna-pk inhibitors for use in anti-tumor therapy
EA201991399A1 (ru) Аминотриазолопиридиновые соединения и их применение в лечении рака
ZA202102999B (en) Inhibitors of cyclin-dependent kinase 7 (cdk7)
PH12020552004A1 (en) Heterocyclic compounds as kinase inhibitors, compositions comprising the heterocyclic compound, and methods of use thereof
PH12020552148A1 (en) Purinone compounds and their use in treating cancer
ZA202003554B (en) 1 -(piperidinocarbonylmethyl)-2-oxopiperazine derivatives for treating cancer
EA201790078A1 (ru) Ингибиторы mnk и связанные с ними способы
EA201100971A1 (ru) Производные пиримидининдола для лечения злокачественного новообразования
EA201892075A1 (ru) Комбинации ингибиторов lsd1 для применения для лечения солидных опухолей
MX2020010942A (es) Inhibidores dobles de atm y adn-pk para uso en terapias antitumorales.
EA201991894A1 (ru) ПИПЕРИДИН-ЗАМЕЩЕННЫЕ ИНГИБИТОРЫ Mnk И СВЯЗАННЫЕ С НИМИ СПОСОБЫ
EA201790779A1 (ru) Замещенные аминопуриновые соединения, их композиции и способы лечения с использованием таких соединений
PH12021550443A1 (en) Pyridazinones and methods of use thereof
PH12021551304A1 (en) Tyrosine kinase inhibitors, compositions and methods there of
ZA202201499B (en) Dual atm and dna-pk inhibitors for use in anti-tumor therapy
ZA202005603B (en) Heterobicyclic inhibitors of mat2a and methods of use for treating cancer
EA201990219A2 (ru) Ингибиторы mek и способы их применения